Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats

Journal of Virology

Volumn 78, Issue 13, 2004, Pages 6808-6817

  Paterna, Jean Charles ^a   Feldon, Joram ^b   Büeler, Hansruedi ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FOREBRAIN; GENE; HIPPOCAMPUS; MALE; MEDIAL FOREBRAIN BUNDLE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARS COMPACTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAAV2 GENE; RAAV5 GENE; RAT; SEROTYPE; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; STEREOTAXIC SURGERY; STRIATE CORTEX; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; BRAIN; CORPUS STRIATUM; DEPENDOVIRUS; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; LUMINESCENT PROTEINS; MALE; MEDIAL FOREBRAIN BUNDLE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINATION, GENETIC; SEROTYPING; SUBSTANTIA NIGRA; TRANSDUCTION, GENETIC;

EID: 2942689239     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.13.6808-6817.2004     Document Type: Article

References (55)

1. Alisky, J. M., S. M. Hughes, S. L. Sauter, D. Jolly, T. W. Dubensky, Jr., P. D. Staber, J. A. Chiorini, and B. L. Davidson. 2000. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport 11:2669-2673.
2. Arvin, B., E. Le Peillet, N. Durmuller, A. G. Chapman, and B. S. Meldrum. 1992. Electrolytic lesions of the locus coeruleus or 6-hydroxydopamine lesions of the medial forebrain bundle protect against excitotoxic damage in rat hippocampus. Brain Res. 579:279-284.
3. Auricchio, A., G. Kobinger, V. Anand, M. Hildinger, E. O'Connor, A. M. Maguire, J. M. Wilson, and J. Bennett. 2001. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum. Mol. Genet. 10:3075-3081.
4. Boulis, N. M., N. E. Willmarth, D. K. Song, E. L. Feldman, and M. J. Imperiale. 2003. Intraneural colchicine inhibition of adenoviral and adeno-associated viral vector remote spinal cord gene delivery. Neurosurgery 52:381-387.
5. Chao, H., Y. Liu, J. Rabinnwitz, C. Li, R. J. Samulski, and C. E. Walsh. 2000. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2:619-623.
6. Chiorini, J. A., F. Kim, L. Yang, and R. M. Kotin. 1999. Cloning and characterization of adeno-associated virus type 5. J. Virol. 73:1309-1319.
7. Chiorini, J. A., L. Yang, Y. Liu, B. Safer, and R. M. Kotin. 1997. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71:6823-6833.
8. Choi-Lundberg, D. L., Q. Lin, Y. N. Chang, Y. L. Chiang, C. M. Hay, H. Mohajeri, & L. Davidson, and M. C. Bohn. 1997. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275:838-841.
9. Costantini, L. C., D. R. Jacoby, S. Wang, C. Fraefel, X. O. Breakefield, and O. Isacson. 1999. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum. Gene Ther. 10:2481-2494.
10. Cucchiarini, M., X. L. Ren, G. Perides, and E. F. Terwilliger. 2003. Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectors. Gene Ther. 10:657-667.
11. Davidson, B. L., C. S. Stein, J. A. Heth, I. Martins, R. M. Kotin, T. A. Derksen, J. Zabner, A. Ghodsi, and J. A. Chiorini. 2000. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. USA 97:3428-3432.
12. Deniau, J. M., A. Menetrey, and S. Charpier. 1996. The lamellar organization of the rat substantia nigra pars reticulata: segregated patterns of striatal afferents and relationship to the topography of corticostriatal projections. Neuroscience 73:761-781.
13. During, M. J., J. R. Naegele, K. L. O'Malley, and A. I. Geller. 1994. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266:1399-1403.
14. Edstrom, A., M. Hanson, M. Wallin, and B. Cederholm. 1979. Inhibition of fast axonal transport and microtubule polymerization in vitro by colchicine and colchiceine. Acta Physiol. Scand. 107:233-237.
15. Frain, O., and V. Leviel. 1998. Mesencephalic THmRNA-reduced expression by blocking axonal transport with colchicine. Neuroreport 9:1529-1532.
16. Gao, G. P., M. R. Alvira, L. Wang, R. Calcedo, J. Johnston, and J. M. Wilson. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 99:11854-11859.
17. Grimm, D., A. Kern, K. Rittner, and J. A. Kleinschmidt. 1998. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9:2745-2760.
18. Grimm, D., S. Zhou, H. Nakai, C. E. Thomas, T. A. Storm, S. Fuess, T. Matsushita, J. Allen, R. Surosky, M. Lochrie, L. Meuse, A. McClelland, P. Colosi, and M. A. Kay. 2003. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102:2412-2419.
19. Hardy, J., M. R. Cookson, and A. Singleton. 2003. Genes and parkinsonism. Lancet Neurol. 2:221-228.
20. Kaludov, N., K. E. Brown, R. W. Walters, J. Zabner, and J. A. Chiorini. 2001. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75:6884-6893.
21. Kaspar, B. K., D. Ericksou, D. Schaffer, L. Hinh, F. H. Gage, and D. A. Peterson. 2002. Targeted retrograde gene delivery for neuronal protection. Mol. Ther. 5:50-56.
22. Kirik, D., B. Georgievska, C. Burger, C. Winkler, N. Muzyczka, R. J. Mandel, and A. Bjorklund. 2002. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc. Natl. Acad. Sci. USA 99:4708-4713.
23. Kirik, D., C. Rosenblad, A. Bjorklund, and R. J. Mandel. 2000. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20:4686-4700.
24. Kitada, T., S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, S. Minoshima, M. Yokochi, Y. Mizuno, and N. Shimizu. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
25. Klein, R. L., M. E. Hamby, Y. Gong, A. C. Hirko, S. Wang, J. A. Hughes, M. A. King, and E. M. Meyer. 2002. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp. Neurol. 176:66-74.
26. Klein, R. L., M. E. Hamby, C. F. Sonntag, W. J. Millard, M. A. King, and E. M. Meyer. 2002. Measurements of vector-derived neurotrophic factor and green fluorescent protein levels in the brain. Methods 28:286-292.
27. Klein, R. L., M. A. King, M. E. Hamby, and E. M. Meyer. 2002. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13:605-612.
28. Kordower, J. H., M. E. Emborg, J. Bloch, S. Y. Ma, Y. Chu, L. Leventhal, J. McBride, E. Y. Chen, S. Palfi, B. Z. Roitberg, W. D. Brown, J. E. Holden, R. Pyzalski, M. D. Taylor, P. Carvey, Z. Ling, D. Trono, P. Hantraye, N. Deglon, and P. Aebischer. 2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-773.
29. Kruger, R., W. Kuhn, T. Muller, D. Woitalla, M. Graeber, S. Kosel, H. Przuntek, J. T. Epplen, L. Schols, and O. Riess. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:106-108.
30. Leroy, E., R. Boyer, G. Auburger, B. Leube, G. Ulm, E. Mezey, G. Harta, M. J. Brownstein, S. Jonnalagada, T. Chernova, A. Dehejia, C. Lavedan, T. Gasser, P. J. Steinbach, K. D. Wilkinson, and M. H. Polymeropoulos. 1998. The ubiquitin pathway in Parkinson's disease. Nature 395:451-452.
31. Lu, Y. Y., L. J. Wang, S. Muramatsu, K. Ikeguchi, K. Fujimoto, T. Okada, H. Mizukami, T. Matsushita, Y. Hanazono, A. Kume, T. Nagatsu, K. Ozawa, and I. Nakano. 2003. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport. Neurosci. Res. 45:33-40.
32. Mastakov, M. Y., K. Baer, R. M. Kotin, and M. J. During. 2002. Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion. Mol. Ther. 5:371-380.
33. Mochizuki, H., H. Hayakawa, M. Migita, M. Shibata, R. Tanaka, A. Suzuki, Y. Shimo-Nakanishi, T. Urabe, M. Yamada, K. Tamayose, T. Shimada, M. Miura, and Y. Mizuno. 2001. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. USA 98:10918-10923.
34. Neet, K. E., and R. B. Campenot. 2001. Receptor binding, internalization, and retrograde transport of neurotrophic factors. Cell. Mol. Life Sci. 58:1021-1035.
35. Nomoto, T., T. Okada, K. Shimazaki, H. Mizukami, T. Matsushita, Y. Hanazono, A. Kume, K. Katsura, Y. Katayama, and K. Ozawa. 2003. Distinct patterns of gene transfer to gerbil hippocampus with recombinant adeno-associated virus type 2 and 5. Neurosci. Lett. 340:153-157.
36. Okada, T., T. Nomoto, K. Shimazaki, W. Lijun, Y. Lu, T. Matsushita, H. Mizukami, M. Urabe, Y. Hanazono, A. Kume, S. Muramatsu, I. Nakano, and K. Ozawa. 2002. Adeno-associated virus vectors for gene transfer to the brain. Methods 28:237-247.
37. Pasquale, G. D., B. L. Davidson, C. S. Stein, I. Martins, D. Scudiero, A. Monks, and J. A. Chiorini. 2003. Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 9:1306-1312.
38. Passini, M. A., D. J. Watson, C. H. Vite, D. J. Landsburg, A. L. Feigenbaum, and J. H. Wolfe. 2003. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J. Virol. 77:7034-7040.
39. Paterna, J. C., and H. Bueler. 2002. Recombinant adeno-associated virus vector design and gene expression in the mammalian brain. Methods 28:208-218.
40. Paterna, J. C., T. Moccetti, A. Mura, J. Feldon, and H. Bueler. 2000. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther. 7:1304-1311.
41. Paxinos, G., and C. Watson. 1986. The rat brain in sterotaxic coordinates, 2nd ed. Academic Press, New York, N.Y.
42. Polymeropoulos, M. H., C. Lavedan, E. Leroy, S. E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E. S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W. G. Johnson, A. M. Lazzarini, R. C. Duvoisin, G. Di Iorio, L. I. Golbe, and R. L. Nussbaum. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
43. Qing, K., C. Mah, J. Hansen, S. Zhou, V. Dwarki, and A. Srivastava. 1999. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5:71-77.
44. Rosenblad, C., D. Kirik, and A. Bjorklund. 2000. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol. 161:503-516.
45. Rutledge, E. A., C. L. Halbert, and D. W. Russell. 1998. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72:309-319.
46. Santarelli, L., M. Saxe, C. Gross, A. Surget, F. Battaglia, S. Dulawa, N. Weisstaub, J. Lee, R. Duman, O. Arancio, C. Belzung, and R. Hen. 2003. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809.
47. Schmajuk, N. A. 2001. Hippocampal dysfunction in schizophrenia. Hippocampus 11:599-613.
48. Summerford, C., J. S. Bartlett, and R. J. Samulski. 1999. αvβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5:78-82.
49. Summerford, C., and R. J. Samulski. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-1445.
50. Tenenbaum, L., F. Jurysta, A. Stathopoulos, Z. Puschban, C. Melas, W. T. Hermens, J. Verhaagen, B. Pichon, T. Velu, and M. Levivier. 2000. Tropism of AAV-2 vectors for neurons of the globus pallidus. Neuroreport 11:2277-2283.
51. Wang, C., C. M. Wang, K. R. Clark, and T. J. Sferra. 2003. Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther. 10:1528-1534.
52. Xiao, W., N. Chirmule, S. C. Berta, B. McCullough, G. Gao, and J. M. Wilson. 1999. Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73:3994-4003.
53. Zabner, J., M. Seiler, R. Walters, R. M. Kotin, W. Fulgeras, B. L. Davidson, and J. A. Chiorini. 2000. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol. 74:3852-3858.
54. Zhang, Y., N. Chirmule, G. Gao, and J. Wilson. 2000. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J. Virol. 74:8003-8010.
55. Zolotukhin, S., B. J. Byrne, E. Mason, I. Zolotukhin, M. Potter, K. Chesnut, C. Summerford, R. J. Samulski, and N. Muzyczka. 1999. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6:973-985.